Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Shares Sold by Shell Asset Management Co.

Shell Asset Management Co. trimmed its stake in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRXGet Rating) by 12.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,041 shares of the specialty pharmaceutical company’s stock after selling 1,781 shares during the period. Shell Asset Management Co. owned about 0.09% of Eagle Pharmaceuticals worth $596,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Allspring Global Investments Holdings LLC purchased a new position in shares of Eagle Pharmaceuticals during the 4th quarter worth approximately $14,018,000. Yousif Capital Management LLC purchased a new position in shares of Eagle Pharmaceuticals during the 4th quarter worth approximately $468,000. Qube Research & Technologies Ltd purchased a new position in shares of Eagle Pharmaceuticals during the 4th quarter worth approximately $499,000. Assenagon Asset Management S.A. increased its stake in shares of Eagle Pharmaceuticals by 21.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 52,080 shares of the specialty pharmaceutical company’s stock worth $2,652,000 after purchasing an additional 9,037 shares in the last quarter. Finally, Pacer Advisors Inc. purchased a new position in shares of Eagle Pharmaceuticals during the 4th quarter worth approximately $1,323,000. 88.71% of the stock is currently owned by institutional investors and hedge funds.

Eagle Pharmaceuticals Price Performance

Shares of EGRX opened at $41.17 on Wednesday. The stock has a market cap of $524.51 million, a price-to-earnings ratio of 14.86 and a beta of 0.61. Eagle Pharmaceuticals, Inc. has a 1-year low of $38.50 and a 1-year high of $58.25. The firm has a 50 day simple moving average of $44.06 and a 200-day simple moving average of $46.17.

Eagle Pharmaceuticals (NASDAQ:EGRXGet Rating) last released its earnings results on Monday, May 9th. The specialty pharmaceutical company reported $3.41 EPS for the quarter, topping the consensus estimate of $3.19 by $0.22. The firm had revenue of $115.87 million during the quarter, compared to analysts’ expectations of $122.39 million. Eagle Pharmaceuticals had a net margin of 14.56% and a return on equity of 18.56%. During the same period in the previous year, the company earned ($0.03) EPS. On average, equities analysts expect that Eagle Pharmaceuticals, Inc. will post 8.22 earnings per share for the current fiscal year.

Eagle Pharmaceuticals Profile

(Get Rating)

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

Featured Articles

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.